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Effects of thyroxine replacement on serum creatinine and
cystatin C in patients with primary and central hypothyroidism
Abstract
BACKGROUND: Serum cystatin C (CysC) is a marker for kidney function, possibly superior to serum
creatinine (Cr). Cr is increased and CysC decreased in primary hypothyroidism; these changes are
reversed upon thyroxine (T4) replacement therapy. This (pilot) study was performed to see whether
these opposing changes of CysC and Cr could be confirmed in patients with central hypothyroidism.
METHODS: Prospective case series of consecutively referred patients with primary and central
hypothyroidism. CysC and Cr were determined at the time of diagnosis and following T4 replacement
therapy. RESULTS: 32 patients with newly diagnosed hypothyroidism were included. In 16 patients
with primary hypothyroidism, mean fT4 was 4.4 +/- 2.5 pmol/l (normal range 12 to 22) at diagnosis and
increased to 20.1 +/- 5.2 pmol/l (p <0.001) following T4 replacement. CysC increased from 0.79 +/-
0.27 mg/l (normal range 0.63 to 1.33) to 1.03 +/- 0.42 mg/l (p = 0.007) whereas Cr declined from 104
+/- 21 micromol/l to 90 +/- 19 micromol/l (p <0.001). In 16 patients with central hypothyroidism, mean
fT4 was 6.5 +/- 1.6 pmol/l at diagnosis and increased to 15.7 +/- 3.3 pmol/l (p <0.001) following T4
replacement. CysC increased from 0.74 +/- 0.27 mg/l to 0.83 +/- 0.30 mg/l (p = 0.01) whereas Cr was
not elevated at baseline (83 +/- 11 micromol/l) and did not decrease following treatment (84 +/- 10
micromol/l). CONCLUSIONS: CysC was low at diagnosis of hypothyroidism and significantly
increased following T4 replacement in patients with primary as well as central hypothyroidism. T4
replacement decreased Cr levels in patients with primary hypothyroidism whereas Cr remained
unchanged in;patients with central hypothyroidism. CysC may not accurately reflect kidney function in
patients with primary and central thyroid dysfunction.
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Background: Serum cystatin C (CysC) is a
marker for kidney function, possibly superior to
serum creatinine (Cr). Cr is increased and CysC
decreased in primary hypothyroidism; these
changes are reversed upon thyroxine (T4) re-
placement therapy. This (pilot) study was per-
formed to see whether these opposing changes of
CysC and Cr could be confirmed in patients with
central hypothyroidism.
Methods: Prospective case series of consecu-
tively referred patients with primary and central
hypothyroidism. CysC and Cr were determined
at the time of diagnosis and following T4 replace-
ment therapy.
Results: 32 patients with newly diagnosed hy-
pothyroidism were included. In 16 patients with
primary hypothyroidism, mean fT4 was 4.4 ± 2.5
pmol/l (normal range 12 to 22) at diagnosis and
increased to 20.1 ± 5.2 pmol/l (p <0.001) follow-
ing T4 replacement. CysC increased from 0.79 ±
0.27 mg/l (normal range 0.63 to 1.33) to 1.03 ±
0.42 mg/l (p = 0.007) whereas Cr declined from
104 ± 21 μmol/l to 90 ± 19 μmol/l (p <0.001). In
16 patients with central hypothyroidism, mean
fT4 was 6.5 ± 1.6 pmol/l at diagnosis and in-
creased to 15.7 ± 3.3 pmol/l (p <0.001) following
T4 replacement. CysC increased from 0.74 ± 0.27
mg/l to 0.83 ± 0.30 mg/l (p = 0.01) whereas Cr
was not elevated at baseline (83 ± 11 μmol/l) and
did not decrease following treatment (84 ± 10
μmol/l).
Conclusions: CysC was low at diagnosis of hy-
pothyroidism and significantly increased follow-
ing T4 replacement in patients with primary as
well as central hypothyroidism. T4 replacement
decreased Cr levels in patients with primary hy-
pothyroidism whereas Cr remained unchanged in
patients with central hypothyroidism. CysC may
not accurately reflect kidney function in patients
with primary and central thyroid dysfunction.
Key words: kidney function; replacement therapy;
thyroid function
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CysC serum cystatin C
fT3 free triiodothyronine
fT4 free thyroxine
GFR glomerular filtration rate
GH growth hormone
IGF-1 insulin-like growth factor-1
Introduction
Serum cystatin C (CysC) has been introduced
as a marker of kidney function and considered to
be an estimator of the glomerular filtration rate
(GFR) at least as good as serum creatinine (Cr) [1,
2]. CysC is a more sensitive marker than Cr, espe-
cially in patients with mildly impaired GFR (in
the “creatinine-blind” range) [3]. It is a low-mole-
cular-weight protein produced at a constant rate
by most nucleated cells independently of age,
gender and lean tissue mass [3–5]. CysC is freely
filtered by the glomerulus, reabsorbed and almost
completely catabolised and destroyed by the tu-
bular epithelial cells [6]. Therefore, GFR is the
major determinant of CysC although the com-
pound is barely excreted in the urine.
Although the production of CysC is not influ-
enced by inflammatory states, serum levels of
CysC may be influenced by hormones [4]. For in-
stance, pharmacological glucocorticoid therapy
increases CysC [7–9]. There is also an impact of
thyroid dysfunction on CysC. CysC levels are
lower in hypothyroid and higher in hyperthyroid
states as compared with the euthyroid state,
changes which are the opposite to those of Cr lev-
els in patients with primary hypo- and hyperthy-
roidism [10–13]. Opposing changes of CysC and
Cr could be confirmed even in patients with sub-
clinical hypo- and hyperthyroidism [14]. Since
the influence of T4 treatment on CysC in central
hypothyroidism has not been investigated, the
aim of this study was to test whether there might
be a difference between the effects of thyroid hor-
mone replacement on Cr and CysC in patients
with primary and central hypothyroidism.
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Materials and methods
Patients with newly diagnosed primary and central
hypothyroidism referred to the Division of Endocrinol-
ogy and Diabetes at the University Hospital in Zurich be-
tween 1998 and 2006 were included. Some of these pa-
tients also took part in two other studies at our institution
[10,15]. Main inclusion criteria were untreated well-doc-
umented overt hypothyroidism at baseline as well as the
possibility of follow-up visits and prospective collection
of blood samples at our division. Patients with impaired
renal function were not excluded. Oral informed consent
to determine additional laboratory values had been ob-
tained from all patients.
Free thyroxine (fT4), free triiodothyronine (fT3),
TSH, CysC, Cr and insulin-like growth factor-1 (IGF-1)
were measured in the hypothyroid state and following
thyroxine replacement therapy after 4 ± 2 months in pa-
tients with primary and after 3 ± 2 months in patients
with central hypothyroidism. Blood samples were taken
before the intake of levothyroxine. In some patients with
central hypothyroidism, blood samples were taken after
glucocorticoids had been administered, either for re-
placement or treatment, depending on the condition in
these patients.
fT4, fT3 and TSH were measured with elec-
trochemoluminescence immunoassay technique on an
Hitachi E170 system, Roche Diagnostics, Rotkreuz,
Switzerland; fT4 with a normal range from 12 to 22
pmol/l and a coefficient of variation (= standard devia-
tion/arithmetic mean) of 2.0% (16.9 pmol/l), fT3 with a
normal range from 2.8 to 7.1 pmol/l and a coefficient of
variation of 4.9% (5.1 pmol/l), TSH with a normal range
from 0.27 to 4.2 mU/l and a coefficient of variation of
2.5% (1.56 mU/l). CysC was measured using an immuno-
logic turbidimetric assay on a Cobas Integra 800 system,
Roche Diagnostics, Rotkreuz, Switzerland, using DAKO
reagents (DAKO Diagnostics, Zug, Switzerland) with a
normal range from 0.63 to 1.33 mg/l and a coefficient of
variation of 3.8% (1.35 mg/l). Cr was measured with the
kinetic Jaffe reaction, rate-blanked with colour compen-
sation on a Hitachi P-Modular system, Roche Diagnos-
tics, Rotkreuz, Switzerland, with a normal range from 62
to 106 μmol/l for men and 44–80 μmol/l for women and a
coefficient of variation of 1.7% (94 μmol/l) [16]. Based on
the recommendations of the National Kidney Founda-
tion the estimated glomerular filtration rate was calcu-
lated using the 4-v MDRD (IDMS) formula: GFR-IDMS
[ml/min/1.73m
2
] = 175 x (creatinine [μmol/l] / 88.4)
–1.154
x
(age)
–0.203
. For women the results were multiplied with
0.742; all of our patients were Caucasians. The MDRD
(IDMS) results [ml/min/1.73 m
2
body surface area] were
adjusted according to Du Bois’ formula for adults (age
>18 y.): body surface area (m
2
) = weight [kg]
0.425
x size
[cm]
0.725
x 0.007184.
IGF-1 was measured by RIA after removal of IGF-
BPs by chromatography; results are expressed in μg/l
[15].
Data are presented as mean values ± SD when nor-
mally distributed and as median and interquartile range
when not normally distributed (TSH). Values before and
after treatment within the two groups were analysed
using paired t-test. Unpaired t-test was performed to
compare data between the two groups (primary hypothy-
roidism versus central hypothyroidism). Non-parametric
tests (Wilcoxon signed rank test and Mann-Whitney U-
test) were used for not normally distributed data (i.e.
TSH). All statistical analyses were performed with Win-
STAT for Excel software. P-values <0.05 were considered
statistically significant.
Results
Primary hypothyroidism
16 patients (10 female) with primary hypothy-
roidism resulting from chronic autoimmune thy-
roiditis (all TPO antibody-positive) were in-
cluded. Mean age at diagnosis was 44 ± 18 years
and BMI was 25.7 ± 6.5 kg/m
2
. All patients were
treated with levothyroxine. 4 ± 2 months later,
fT4, fT3, IGF-1 and CysC as well as heart rate
had increased whereas TSH, Cr and diastolic
blood pressure had fallen significantly. Seven of
16 patients at baseline met screening criteria for
impaired renal function (estimated GFR ≤60
ml/min using the 4-v MDRD). At follow-up, the
estimated GFR rose to >60 ml/min in two of the
seven patients with impaired renal function at
baseline. Laboratory results at baseline and fol-
lowing T4 treatment are shown in Table 1. With
the exception of one patient with primary hy-
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primary central central vs primary
hypothyroidism hypothyroidism
difference (95% CI) p values
(n = 16) (n = 16)
fT4 (pmol/L, normal range 12–22)
baseline (hypothyroid) 4.4 ± 2.5 6.5 ± 1.6 2.1 (0.6–3.7) 0.01
follow-up (euthyroid) 20.1 ± 5.2 15.7 ± 3.3 –4.4 (–7.7 to –1.2) 0.009
follow-up vs baseline: <0.001 <0.001
p values
change (95% CI) +15.7 (13.2–18.3) +9.2 (7.2–11.1) <0.001
fT3 (pmol/L, normal range 2.8–7.1)
baseline 2.1 ± 0.7 3.4 ± 1.1 1.3 (0.6–1.9) <0.001
follow-up 5.0 ± 1.2 4.0 ± 0.6 –1 (–1.7 to –0.3) 0.006
follow-up vs baseline: <0.001 0.02
p values
change (95% CI) +2.9 (2.1–3.7) +0.6 (0.1–1.1) <0.001
TSH (mU/L, normal range 0.27–4.2)
baseline 89 (62–319) 1.8 (1.1–2.6) 0.001
follow-up 2.2 (0.38–3.35) 0.25 (0.1–0.48) <0.001
follow-up vs baseline: 0.001 0.01
p values
CysC (mg/L, normal range 0.63–1.33)
baseline 0.79 ± 0.27 0.74 ± 0.27 –0.05 (–0.25–0.15) 0.62
follow-up 1.03 ± 0.42 0.83 ± 0.30 –0.2 (–0.47–0.07) 0.14
follow-up vs baseline: 0.007 0.01
p values
change (95% CI) +0.24 (0.08–0.41) +0.09 (0.03–0.16) 0.079
Cr (μmol/L) baseline 104 ± 21 83 ± 11 –21 (–33 to –8) 0.003
follow-up 90 ± 19 84 ± 10 –6 (–18–4) 0.21
follow-up vs baseline: <0.001 0.7
p values
change (95% CI) –14 (–19 to –8) +1 (–3–4) <0.001
IGF-1 (μg/L) baseline 111 ± 57 64 ± 29 –47 (–81 to –14) 0.008
follow-up 153 ± 45 99 ± 42 –54 (–86 to –21) 0.002
follow-up vs baseline: 0.01 <0.001
p values
change (95% CI) +42 (12–72) +35 (21–50) 0.684
Systolic blood baseline 127 ± 19 123 ± 25 –4 (–20–11) 0.58
pressure (mm Hg)
follow-up 122 ± 14 125 ± 19 3 (–9–16) 0.58
follow-up vs baseline: 0.07 0.37
p values
change (95% CI) –5 (–11 to –0.5) +2 (–3.5–9.5) 0.058
Diastolic blood baseline 80 ± 10 78 ± 11 –2 (–10–6) 0.57
pressure (mm Hg)
follow-up 72 ± 7 80 ± 9 8 (2–14) 0.009
follow-up vs baseline: 0.006 0.34
p values
change (95% CI) –8 (–13 to –4.5) +2 (–3–8) 0.002
Heart rate (beats/min)
baseline 64 ± 9 69 ± 8 5 (–1–11) 0.11
follow-up 71 ± 7 71 ± 10 0 (–5–7) 0.81
follow-up vs baseline: <0.001 0.21
p values
change (95% CI) +7 (4.5 – 11.5) +2 (-2–7.5) 0.072
Data are presented as mean values ± SD when normally distributed. Not normally distributed parameters are presented as medians
and interquartile ranges (TSH).
Table 1
Response toT4
replacement therapy.
pothyroidism whose blood pressure was not
recorded at follow-up visit, the data for all out-
come measures were available.
Central hypothyroidism
16 patients (9 female) with central hypothy-
roidism due to pituitary tumours or cranio-
pharyngiomas were included. Mean age at diag-
nosis was 45 ± 18 years and BMI was 26.4 ± 4.5
kg/m
2
. Four patients had a macro-prolactinoma,
five had a non-functioning macro-adenoma and
seven had a craniopharyngioma. In addition to
TSH deficiency, all these patients were also lack-
ing gonadotropins (and sex hormones) and most
of them growth hormone (GH). 11 patients had
ACTH deficiency. Among these 11 patients, four
patients were on dexamethasone (pharmacologi-
cal glucocorticoid treatment) and two patients on
hydrocortisone (replacement) therapy when base-
line values were determined. Five patients with
ACTH deficiency were not on glucocorticoid
treatment when the baseline blood samples were
taken.At follow-up, 14 patients were on glucocor-
ticoid replacement (three of them for safety rea-
sons). Glucocorticoids were given for replace-
ment and therefore at low doses in all patients at
the time of follow-up.
All patients were treated with levothyroxine.
At follow-up, fT4 had increased but heart rate
and blood pressure remained unchanged. Labora-
tory results at baseline and following T4 treat-
ment are shown in table 1.
In contrast to patients with primary hypothy-
roidism, Cr was not increased at baseline and did
not change after T4 replacement whereas CysC
increased in the same period. Two of 16 patients
met screening criteria for impaired renal function
(estimated GFR using the 4-v MDRD based for-
mula ≤60 ml/min) both at baseline and at follow-
up. Serum IGF-1 concentrations before and after
T4 therapy were lower compared to patients with
primary hypothyroidism but there was also a sig-
nificant increase following T4 replacement. An
increase in CysC in response to T4 was also ob-
served in the six patients already on glucocorti-
coids at baseline (0.74 mg/l at baseline, 0.89 mg/l
at follow-up) and in those (two patients) never
treated with corticosteroids (0.54 mg/l at base-
line, 0.65 mg/l at follow-up).
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Discussion
Thyroid dysfunction has been associated with
changes in kidney function, Cr, and CysC. Pri-
mary hypothyroidism results in an increase in Cr,
reflecting a reduction in GFR most likely due to
decreased renal blood flow [17–21] and T4 re-
placement results in a decrease of Cr levels. The
changes of CysC concentrations in primary hy-
pothyroidism are inverse to changes in Cr, i.e.,
CysC concentrations are low in the hypothyroid
state and increase in response to T4 replacement.
In this study we show that such inverse changes of
Cr and CysC in patients with primary hypothy-
roidism cannot be confirmed in patients with cen-
tral hypothyroidism.
At baseline, Cr was significantly higher in pa-
tients with primary hypothyroidism than in those
with central hypothyroidism, and more of these
patients had impaired renal function as judged by
estimated GFR ≤60 ml/min using the 4-v MDRD.
This difference between the two groups was no
longer found after T4 replacement. Although thy-
roid hormone depletion was less severe in patients
with central hypothyroidism, milder thyroid hor-
mone deficiency cannot fully account for such a
difference since Cr also increases in mild primary
hypothyroidism [14]. In patients with central hy-
pothyroidism, Cr levels were not increased at
baseline and remained unchanged whereas CysC
concentrations increased upon T4 replacement.
This finding supports the hypothesis that the
CysC production may be influenced by thyroid
hormones. The absolute change of CysC levels in
patients with central hypothyroidism was less pro-
nounced than the changes observed in patients
with primary hypothyroidism. This might be ex-
plained by smaller increase in fT3 concentrations
in patients with central hypothyroidism compared
to patients with primary hypothyroidism, indicat-
ing less severe hypothyroidism at baseline and less
impact of T4 replacement in patients with central
hypothyroidism.
CysC concentration may slightly differ be-
tween males and females. According to a study of
Stevens et al [22], CysC was 9.2% lower in fe-
males than in males (after adjustment for GFR).
Since we had almost an equal number of women
in both groups (62.5 vs 56.3%), the influence of
gender on the results will be minimal.
Thyroid hormone deficiency in patients with
primary hypothyroidism results in endothelial
dysfunction which can be corrected by T4 re-
placement [23, 24]. In our patients with central
hypothyroidism, diastolic blood pressure, which is
associated with endothelial dysfunction, was not
increased at baseline and did not fall in response
to T4 replacement therapy, whereas in patients
with primary hypothyroidism, diastolic blood
pressure was increased at baseline and fell signifi-
cantly after T4 replacement therapy.
An obvious difference between patients with
central vs patients with primary hypothyroidism
is the TSH level (table 1) which is markedly in-
creased in the latter only. In this context it may be
of interest that TSH per se could possibly impair
endothelium-dependent vasodilatation and could
be partly responsible for the elevated blood pres-
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sure and impaired renal function seen in patients
with primary hypothyroidism [25].
Apart from TSH and thyroid hormones,
other pituitary-dependent hormones could affect
kidney function and Cr.
GH is the major stimulus for IGF-1 expres-
sion by hepatocytes. IGF-1 improves endothelial
function, renal blood flow and raises GFR by a re-
duction of the efferent arteriolar resistance [26].
Serum concentration of IGF-1 is decreased in hy-
pothyroidism and increased by T4 therapy in pri-
mary hypothyroidism and to somewhat lower lev-
els in patients with central hypothyroidism re-
flecting that the patients with central hypothy-
roidism were (and remained) deficient in GH
(table 1) [15]. In this context, it should be men-
tioned that GH and/or IGF-1 not only enhance
the generation but also the biological actions of
T3, possibly also explaining the smaller effects of
T4 on CysC in patients with central hypothy-
roidism in our study [27]. Moreover, we cannot
exclude the possibility that our empirical (symp-
tom-, sign- and fT4-guided) T4-dosage was sub-
optimal with regard to normalising metabolism
and CysC [28, 29].
Prolactin was not routinely assessed in pa-
tients with primary hypothyroidism but was
markedly elevated at baseline in the four patients
with macroprolactinoma, and moderately in-
creased in some of the other patients with pitu-
itary and thyroid disorders. Prolactin was not as-
sociated with changes in CysC, but due to the
limited number of patients our data neither sug-
gest nor exclude an influence of prolactin on
CysC.
High dose glucocorticoid therapy has been
reported to increase CysC. In renal transplant re-
cipients CysC increased in patients with corticos-
teroid therapy after renal transplantation [30]. In
such studies, however, nephrotoxic calcineurin in-
hibitor treatment could also contribute to differ-
ential increases in CysC and Cr after renal trans-
plantation. In a more recent study, high-dose glu-
cocorticoid therapy for nephrotic syndrome did
not significantly increase CysC level in five chil-
dren with high GFRs [8]. In vitro, dexamethasone
produces a significant and dose-dependent in-
crease in CysC expression in HeLa cells [31].We
confirmed stimulatory effects of dexamethasone
on CysC mRNA in cultured bone and lung cells,
and we found stimulatory effects of T3 in vitro
[Schmid. et al., in preparation].
To our knowledge, there are no data on the
effect of cortisol deficiency and replacement on
kidney function, Cr or CysC. In our study, an ef-
fect of (low-dose) glucocorticoid replacement
therapy on Cr and CysC in patients with central
hypothyroidism is difficult to confirm or to ex-
clude because of the heterogeneity of glucocorti-
coid deficiency and therapy at baseline and at fol-
low-up. Apparently, it could not mask a stimula-
tory effect of T4, since CysC levels increased at
follow-up even in the six patients on glucocorti-
coid therapy at baseline. The small number of pa-
tients in this subgroup precluded meaningful sta-
tistical analysis. We found that the impact of T4
replacement therapy on CysC level was important
in both primary and central hypothyroidism, irre-
spective of glucocorticoid therapy.
A major limitation of our study is the fact that
the analysis of kidney function was restricted to
serum markers and did not include direct meas-
urement of GFR by clearance of inulin, radionu-
clides or radiocontrast agents. Formulae such as
the 4-v MDRD have been used for Cr-based esti-
mation of GFR and have been validated in larger
cohorts, including elderly people. However, these
formulae lack precision for individuals with GFR
>60 ml/min and they have not been validated for
patients suffering from pituitary failure.The same
is true for serum markers. Both CysC and Cr are
remarkably low in central hypothyroidism and
possibly overestimate GFR in these patients.
CysC may not accurately reflect kidney function
in patients with primary and central thyroid
dysfunction. To fully elucidate the relationship
between thyroid function, CysC and Cr concen-
tration, further research with larger sample sizes
is needed to correct the analysis for age, sex, body
composition, renal function, differences in under-
lying disease, baseline, pattern and severity of
pituitary failure and hormonal replacement thera-
pies (in patients with central hypothyroidism).
Furthermore, direct measurement of GFR should
be considered. Our pilot study suggests that CysC
may be among the more sensitive surrogate pa-
rameters reflecting thyroid hormone action not
only in primary but also in central hypothy-
roidism.
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